Development of MYELO001 as an orally applied medical countermeasure for the treatment of hematopoietic acute radiation syndrome

Ended Definitive Contract Awarded Last action

Contract number
75N93020C00005
Awardee
Awarding agency
Obligated
$6,728,096

Award facts

Opportunity
Contract value 100% obligated
$6,728,096.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 7 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Germany
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00022 $0
Other Administrative Action P00021 $0
Other Administrative Action P00020 $0
Other Administrative Action P00019 $0
Other Administrative Action P00018 $0
Funding Only Action P00017 $219,300
Other Administrative Action P00016 $0
Other Administrative Action P00015 $0
Other Administrative Action P00014 $0
Other Administrative Action P00013 $0
Other Administrative Action P00012 · IPP: development of MYELO001 as an orally applied medical countermeasure for the treatment of hematopoietic acute radiation syndrome $0
Other Administrative Action P00011 $0
Exercise an Option P00010 $1,996,255
Other Administrative Action P00009 $0
Other Administrative Action P00008 $0
Other Administrative Action P00007 $0
Other Administrative Action P00006 $290,266
Other Administrative Action P00005 $0
Exercise an Option P00004 $1,969,335
Other Administrative Action P00003 $259,708
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $1,993,232
Show all 23

About this award

Written by GovTribe AI ·

The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,728,096.00 cost-plus-fixed-fee definitive contract to Myelo Therapeutics GmbH, a for-profit limited liability company, for the development of MYELO001 as an orally applied medical countermeasure to treat hematopoietic acute radiation syndrome. This contract, which has a completion date of January 16, 2025, stems from a Broad Agency Announcement seeking proposals to develop safe and effective medical countermeasures that can mitigate and/or treat tissue injuries from ionizing radiation exposure in a radiological or nuclear incident, with the goal of reducing radiation-associated morbidities and mortalities when strategic national stockpile drugs may not be available within the first 24 hours. The contract does not have a set-aside designation.

Quick answers

Who was awarded contract 75N93020C00005?

75N93020C00005 was awarded to Myelo Therapeutics GMBH by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 1, 2020.

How much is contract 75N93020C00005 worth?

The government has obligated $6,728,096 on 75N93020C00005.

Was contract 75N93020C00005 competed?

The extent of competition for 75N93020C00005 was full and open competition. The government received 7 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login